JP2016504308A - 抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 - Google Patents
抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 Download PDFInfo
- Publication number
- JP2016504308A JP2016504308A JP2015546546A JP2015546546A JP2016504308A JP 2016504308 A JP2016504308 A JP 2016504308A JP 2015546546 A JP2015546546 A JP 2015546546A JP 2015546546 A JP2015546546 A JP 2015546546A JP 2016504308 A JP2016504308 A JP 2016504308A
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- cell
- amino acid
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 107
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 107
- 108091007433 antigens Proteins 0.000 title claims abstract description 87
- 102000036639 antigens Human genes 0.000 title claims abstract description 87
- 239000000427 antigen Substances 0.000 title claims abstract description 86
- 230000005867 T cell response Effects 0.000 title claims abstract description 15
- 239000003623 enhancer Substances 0.000 title abstract description 4
- 230000002163 immunogen Effects 0.000 title abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 138
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 230000005945 translocation Effects 0.000 claims abstract description 57
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 47
- 230000011664 signaling Effects 0.000 claims abstract description 45
- 230000001235 sensitizing effect Effects 0.000 claims abstract description 43
- 230000026683 transduction Effects 0.000 claims abstract description 40
- 238000010361 transduction Methods 0.000 claims abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 39
- 230000004927 fusion Effects 0.000 claims abstract description 36
- 229920001184 polypeptide Polymers 0.000 claims abstract description 34
- 244000052769 pathogen Species 0.000 claims abstract description 30
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims abstract description 27
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 25
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 23
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 52
- 229960005486 vaccine Drugs 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 35
- 230000014759 maintenance of location Effects 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 claims description 3
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 241000701806 Human papillomavirus Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 9
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 230000024932 T cell mediated immunity Effects 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 230000000091 immunopotentiator Effects 0.000 description 7
- 229940123205 CD28 agonist Drugs 0.000 description 6
- 241001673669 Porcine circovirus 2 Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000004172 Cathepsin L Human genes 0.000 description 5
- 108090000624 Cathepsin L Proteins 0.000 description 5
- 241000711549 Hepacivirus C Species 0.000 description 5
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108090001126 Furin Proteins 0.000 description 4
- 102000004961 Furin Human genes 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108700025184 hepatitis B virus X Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 3
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 3
- 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 3
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 3
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 3
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 3
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 3
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 3
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 3
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 3
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 3
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 3
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 3
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 3
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 3
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 3
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 3
- 108010003718 LDL-Receptor Related Protein-Associated Protein Proteins 0.000 description 3
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101710087110 ORF6 protein Proteins 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 3
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 3
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 3
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 3
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 3
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 3
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 3
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 3
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 3
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 3
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 3
- 230000000274 adsorptive effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 101000636214 Arabidopsis thaliana Transcription factor MYC2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010058141 LDL-Receptor Related Proteins Proteins 0.000 description 1
- 102000006259 LDL-Receptor Related Proteins Human genes 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
分子生物学は、サブユニットワクチンの生産を可能にした。免疫原は、親タンパク質又は複合体の断片又はサブユニットである。T細胞感作反応を誘発することができ、病原菌の多くの株由来の配列を組み込むのに十分な柔軟性がある安定ワクチンの開発が望まれている。
一つの態様では、本発明は、融合タンパク質であって、上記融合タンパク質は、
(a) 上記融合タンパク質のN末端に位置する、抗原提示細胞(APC)-結合ドメイン又はCD91受容体-結合ドメイン;
(b) 上記APC-結合ドメイン又は上記CD91受容体-結合ドメインのC末端に位置するタンパク質トランスダクションドメインであって、
(i) T細胞感作シグナル伝達ペプチド、リンカー及びトランスロケーションペプチドを含む融合ポリペプチドであって、
(1) 上記T細胞感作シグナル伝達ペプチドは、上記融合ポリペプチドのN末端に位置し、
(2) 上記リンカーは、配列番号:15を含み、且つ、上記T細胞感作シグナル伝達ペプチドとトランスロケーションペプチドとを結合し、
(3) 上記トランスロケーションペプチドは、長さ34-112のアミノ酸残基を有し、配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、融合ポリペプチドと、
(ii) T細胞感作シグナル伝達ペプチドと、
(iii) 配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、長さ34-112のアミノ酸残基のトランスロケーションペプチドからなる群より選択される上記タンパク質トランスダクションドメイン;及び、
(c) 上記タンパク質トランスダクションドメインのC末端に位置する、病原体の抗原;を含み、
上記T細胞感作シグナル伝達ペプチドは、長さ28-53のアミノ酸残基を有し、配列番号:31と少なくとも90%同一のアミノ酸配列を含み、Xaa8はI又はLであり、Xaa10はV、F又はAであり、Xaa11はM又はLであり、Xaa17はL又はIであり、
上記APC-結合ドメイン又は上記CD91受容体-結合ドメインは、上記タンパク質トランスダクションドメインが上記トランスロケーションペプチド(biii)である場合、シュードモナスエキソトキシンA(PE)結合ドメインIのアミノ酸配列を有さない、融合タンパク質に関する。
(a) 上記融合タンパク質のN末端に位置するCD91受容体-結合ドメイン又は抗原提示細胞(APC)-結合ドメイン;
(b) 上記APC-結合ドメイン又はCD91受容体-結合ドメインのC末端に位置するタンパク質トランスダクションドメインであって、
(i) T細胞感作シグナル伝達ペプチド、リンカー及びトランスロケーションペプチドを含む融合ポリペプチドであって、
(1) T細胞感作シグナル伝達ペプチドは、上記融合ポリペプチドのN末端に位置し、
(2) 上記リンカーは、配列番号:15を含み、且つ、上記T細胞感作シグナル伝達ペプチドとトランスロケーションペプチドとを結合し、
(3) 上記トランスロケーションペプチドは、長さ34-112のアミノ酸残基を有し、配列番号:3、20又は4と少なくとも90%同一であるアミノ酸配列を含む、融合ポリペプチドと、
(ii) T細胞感作シグナル伝達ペプチドと、
(iii) 配列番号:3、20又は4と少なくとも90%同一であるアミノ酸配列を含む、長さ34-112のアミノ酸残基のトランスロケーションペプチドからなる群より選択されるタンパク質トランスダクションドメイン;及び、
(C) 上記タンパク質トランスダクションドメインのC末端に位置する病原体の抗原;、からなり、
上記T細胞感作シグナル伝達ペプチドは、長さ28-53のアミノ酸残基を有し、配列番号:31と少なくとも90%同一であるアミノ酸配列を含み、Xaa8はI又はLであり、Xaa10はV、F又はAであり、Xaa11はM又はLであり、Xaa17はL又はIであり、
上記タンパク質トランスダクションドメインがトランスロケーションペプチド(biii)である場合、上記APC-結合ドメイン又はCD91受容体-結合ドメインは、シュードモナスエキソトキシンA(PE)ドメインIのアミノ酸配列を有さない。
本発明は、以下の実施例に特に記載されている。多数の変更形態及びバリエーションが当業者にとって明らかであるため、実施例は、説明のためであることを意図している。以下、本発明の様々な実施形態の詳細について説明する。図面に関して、同じ番号は、図全体にわたって、同じ構成要素を示す。本願明細書及び添付の請求項全体に渡る記述において使用している通り、「a」、「an」及び「the」の意味は、文脈において別途明確に示していない限り、複数を含むまた、本願明細書及び添付の請求項全体に渡る記述において使用している通り、「in」の意味は、文脈において別途明確に示していない限り、「in」及び「on」を含む。さらに、表題又は副題は、読者の便宜のために明細書において使用されているが、本発明の範囲に対する影響を及ぼすものではない。加えて、この明細書において使用するある種の用語は、下でより詳しくは規定している。
この明細書において使用する用語は、一般的に、本発明の背景内の技術分野、及び、各用語が使用されている特定の文脈における通常の意味を有する。本発明を説明するために用いるある種の用語は、本発明の記述に関して実践者に追加のガイダンスを提供するために、以下、又は、別途明細書中にて説明する。便宜上、ある種の用語は、例えば、イタリック及び/又は引用符を使用して、強調されているだろう。強調表示の使用は、用語の範囲及び意味に対する影響を与えない。用語の範囲及び意味は、それが強調されていようといまいと、同じ文脈において同じである。同じことを複数の方法で述べることができることはいうまでもない。その結果、代替の言葉及び同義語を、本願明細書において述べられる任意の1又は複数の用語のために用いることができるが、本願明細書において詳しく述べている又は議論されているか否かによって与えられる任意の特別な用語ではない。ある種の用語には同義語が提供される。1又は複数の同義語の記載は、他の同義語の使用を排除しない。この明細書における例示(本願明細書に記載の任意の用語の例示を含む)の使用は、解説のためだけにあり、本発明又は任意の例示用語の範囲及び意味を限定するものではない。同様に、本発明は、この明細書が提供する様々な実施形態に限定されない。
(i) T細胞感作シグナル伝達ペプチド、リンカー及びトランスロケーションペプチドを含む融合ポリペプチドであって、
(1) 上記T細胞感作シグナル伝達ペプチドは、融合ポリペプチドのN末端に位置し、
(2) 上記リンカーは、配列番号: 15を含み、且つ、上記T細胞感作シグナル伝達ペプチド及びトランスロケーションペプチドを結合し、
(3) 上記トランスロケーションペプチドは、長さ34-112のアミノ酸残基を有し、配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、融合ポリペプチド;
(ii) T細胞感作シグナル伝達ペプチド;
(iii) 配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、長さ34-112のアミノ酸残基のトランスロケーションペプチド;からなる群より選択されるペプチド及び/又はポリペプチドであってもよい。
発現ベクターの構造
図1は、融合タンパク質RAP1-PE268-313-E7-K3の発現ベクターを示す。これは、RAP1ドメイン3(配列番号:5)、トランスロケーション最小必須ペプチド(PE268-313;配列番号:20)、抗原E7及び小胞体リテンション配列(K3又はKDELシグナル;配列番号:16、17、18、又は19)を含む。トランスロケーション最小必須ペプチド(PE268-313;配列番号:20)は、a.a.268からa.a.313のPE(配列番号:10)ポリペプチド配列領域から得られた。
タンパク質発現
タンパク質発現ベクターを含む大腸菌BL21細胞を、25μg/mlのカナマイシンを含むルーリアベルターニブロス中で37℃で培養した。培養が初期対数期(A600=0.1から0.4)に到達すると、誘導のためにイソプロピル-1-チオ-β-D-ガラクトピラノシド(IPTG)を0.5〜2mMの終濃度で加えた。IPTG誘導の4時間後、細胞を回収して、超音波処理によって破壊した。過剰発現タンパク質含有封入体を単離して、8Mの尿素/TN緩衝液(8Mの尿素、50mMのトリス、50mMのNaCl、pH 8.0)に可溶化した。
RAP1-PE268-313-E7-K3は、ヒトパピローマウイルス(HPV)タイプ16 E7タンパク質によって誘導される腫瘍の成長を阻害する。
融合タンパク質PE407-E7-K3及びRAP1-PE268-313-E7-K3は、上記の通りに発現させて、SDS-PAGE(図5B)によってタンパク質リフォールディングを検討した。s.c.注射を介して2×103のTC-01細胞(HPVタイプ16 E7遺伝子を含むマウス肺上皮細胞株)をマウスに投与して、HPV-16タイプ上皮性悪性腫瘍を誘導した。TC-01細胞投与の12日後、1週1回を3週間、アジュバントとしてのAS04C(グラクソスミスクライン)と共に、プラセボ(PBS+リン酸アルミニウム)、PE407-E7-K3(200μg/投与)又はRAP1-PE268-313-E7-K3(200μg/投与)をs.c.にてマウスにワクチン接種した(図5A)。AS04Cは、細胞毒性Tリンパ球向上アジュバントであり、MPL(モノホスホリルリピドA、免疫強化剤)及びリン酸アルミニウム(抗原デリバリーのためのタンパク質吸着剤)を含む。「K3」という用語は、アミノ酸配列KDELKDELKDEL(配列番号:19)を表す。各群における腫瘍のサイズ及び腫瘍がない動物の数を記録した(図5C-D)。腫瘍成長は、アジュバントとしてのAS04Cを有するワクチンPE407-E7-K3及びRAP1-PE268-313-E7-K3によって著しく抑制された。しかしながら、RAP1-PE268-313-E7-K3によるワクチン接種を受けたマウス群は、腫瘍がないマウスの割合が高かった。これは、ワクチンRAP1-PE268-313-E7-K3は、腫瘍成長の抑制についてPE407-E7-K3と同じくらい有効又はそれよりも有効であるが、腫瘍がない動物のパーセンテージはより増加することを示している。
RAP1-CD28convPEt-E7-K3は、ヒトパピローマウイルス(HPV)タイプ16 E7タンパク質によって誘導された腫瘍の成長を阻害して、生存率を増加させる。
免疫原性アッセイ
様々なワクチンの免疫原性を試験した。簡潔にいえば、マウスを以下の群に分けた。HPV16 E7、HPV 18 E7、HCVコア、HBV HBx、PCV2 ORF2及びPRRSV(図13A)。各群をサブ群に更に分けて、1週1回を3週間間、病原体の1又は複数のある種の抗原を標的にするように設計したワクチン又はプラセボを各サブ群にs.c.を経て投与した(図13B)。PRRSVを標的にしたワクチンを除いて、各ワクチンは、単一の融合タンパク質及び吸着性リン酸アルミニウムから構成した。単一の融合タンパク質は、少なくとも病原体の抗原を含むこととした。抗原は、病原体由来の全長タンパク質又は病原体の抗原の少なくとも一つのエピトープを含む若しくは2以上の抗原の融合ペプチドである非全長タンパク質とした。各抗原は、病原体の種々のタンパク質から選択した。
DGDは、PRRSV ORF7 a.a.64 - a.a.123(太字)、リンカー(下線)及びORF7 a. a.64 - a.a.123(太字)の融合抗原を表す。
NNKECTVAQALGNGDKFRATDKRVVDSLRAICADLEGSSSPLPKVAHNLGFYFSPDLTQFAKLPIELAPHWPVVSTQNNEKWPDRLVASLRPLDKYSRACIGAGYMVGPSVFLGTPGVVSYYLTKFVKGEAQVLPETVFSTGRIEVDCREYLDDREREVAASLPH。
GSSLDDFCYDSTAPQKVLLAFSITYASNDSSSHLQLIYNLTLCELNGTDWLANKFDWA。
PQABは、PRRSVアメリカン株ORF6 a.a.2 - a.a.26及びORF5 a.a.31 - a.a.63(下線)の融合抗原を表す。
融合タンパク質RAP1-CD28convPEt-E7-K3のRAP1ドメイン3の断片を、A2Mミニマム(配列番号:6)、HIV-Tatミニマム(配列番号:7)又はHSPミニマム(配列番号:8)と置き換えて、融合タンパク質A2M-CD28convPEt-E7-K3、Tat-CD28convPEt-E7-K3及びHSP-CD28convPEt-E7-K3ワクチンをそれぞれ生成する。これらのワクチンによって向上した細胞性免疫反応及びTC-1腫瘍抑制活性は、上記方法と類似の方法を使用して検討する。表1は、様々な融合タンパク質の構成成分の配列番号を示している。表2は、動物のT細胞性免疫応答に対する効果に関して試験した融合タンパク質及び抗原の配列を示している。
一つの態様では、本発明は、融合タンパク質であって、上記融合タンパク質は、
(a) 上記融合タンパク質のN末端に位置する、抗原提示細胞(APC)-結合ドメイン又はCD91受容体-結合ドメイン;
(b) 上記APC-結合ドメイン又は上記CD91受容体-結合ドメインのC末端に位置するタンパク質トランスダクションドメインであって、
(i) T細胞感作シグナル伝達ペプチド、リンカー及びトランスロケーションペプチドを含む融合ポリペプチドであって、
(1) 上記T細胞感作シグナル伝達ペプチドは、上記融合ポリペプチドのN末端に位置し、
(2) 上記リンカーは、配列番号:15を含み、且つ、上記T細胞感作シグナル伝達ペプチドとトランスロケーションペプチドとを結合し、
(3) 上記トランスロケーションペプチドは、長さ34-112のアミノ酸残基を有し、配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、融合ポリペプチドと、
(ii) T細胞感作シグナル伝達ペプチドと、
(iii) 配列番号:3又は20と少なくとも90%同一のアミノ酸配列を含む、長さ34-46のアミノ酸残基のトランスロケーションペプチドからなる群より選択される上記タンパク質トランスダクションドメイン;及び、
(c) 上記タンパク質トランスダクションドメインのC末端に位置する、病原体の抗原;を含み、
上記T細胞感作シグナル伝達ペプチドは、長さ28-53のアミノ酸残基を有し、配列番号:31のアミノ酸配列を含み、Xaa8はI又はLであり、Xaa10はV、F又はAであり、Xaa11はM又はLであり、Xaa17はL又はIであり、
上記APC-結合ドメイン又は上記CD91受容体-結合ドメインは、上記タンパク質トランスダクションドメインが上記トランスロケーションペプチド(biii)である場合、シュードモナスエキソトキシンA(PE)結合ドメインIのアミノ酸配列を有さない、融合タンパク質に関する。
(a) 上記融合タンパク質のN末端に位置するCD91受容体-結合ドメイン又は抗原提示細胞(APC)-結合ドメイン;
(b) 上記APC-結合ドメイン又はCD91受容体-結合ドメインのC末端に位置するタンパク質トランスダクションドメインであって、
(i) T細胞感作シグナル伝達ペプチド、リンカー及びトランスロケーションペプチドを含む融合ポリペプチドであって、
(1) T細胞感作シグナル伝達ペプチドは、上記融合ポリペプチドのN末端に位置し、
(2) 上記リンカーは、配列番号:15を含み、且つ、上記T細胞感作シグナル伝達ペプチドとトランスロケーションペプチドとを結合し、
(3) 上記トランスロケーションペプチドは、長さ34-112のアミノ酸残基を有し、配列番号:3、20又は4と少なくとも90%同一であるアミノ酸配列を含む、融合ポリペプチドと、
(ii) T細胞感作シグナル伝達ペプチドと、
(iii) 配列番号:3又は20と少なくとも90%同一であるアミノ酸配列を含む、長さ34-46のアミノ酸残基のトランスロケーションペプチドからなる群より選択されるタンパク質トランスダクションドメイン;及び、
(C) 上記タンパク質トランスダクションドメインのC末端に位置する病原体の抗原;、からなり、
上記T細胞感作シグナル伝達ペプチドは、長さ28-53のアミノ酸残基を有し、配列番号:31のアミノ酸配列を含み、Xaa8はI又はLであり、Xaa10はV、F又はAであり、Xaa11はM又はLであり、Xaa17はL又はIであり、
上記タンパク質トランスダクションドメインがトランスロケーションペプチド(biii)である場合、上記APC-結合ドメイン又はCD91受容体-結合ドメインは、シュードモナスエキソトキシンA(PE)ドメインIのアミノ酸配列を有さない。
Claims (20)
- 融合タンパク質であって、上記融合タンパク質は、
(a) 上記融合タンパク質のN末端に位置する、抗原提示細胞(APC)-結合ドメイン又はCD91受容体-結合ドメイン;
(b) 上記APC-結合ドメイン又は上記CD91受容体-結合ドメインのC末端に位置するタンパク質トランスダクションドメインであって、
(i) T細胞感作シグナル伝達ペプチド、リンカー及びトランスロケーションペプチドを含む融合ポリペプチドであって、
(1) 上記T細胞感作シグナル伝達ペプチドは、上記融合ポリペプチドのN末端に位置し、
(2) 上記リンカーは、配列番号:15を含み、且つ、上記T細胞感作シグナル伝達ペプチドとトランスロケーションペプチドとを結合し、
(3) 上記トランスロケーションペプチドは、長さ34-112のアミノ酸残基を有し、配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、融合ポリペプチドと、
(ii) T細胞感作シグナル伝達ペプチドと、
(iii) 配列番号:3、20又は4と少なくとも90%同一のアミノ酸配列を含む、長さ34-112のアミノ酸残基のトランスロケーションペプチドからなる群より選択される上記タンパク質トランスダクションドメイン;及び、
(c) 上記タンパク質トランスダクションドメインのC末端に位置する、病原体の抗原;を含み、
上記T細胞感作シグナル伝達ペプチドは、長さ28-53のアミノ酸残基を有し、配列番号:31と少なくとも90%同一のアミノ酸配列を含み、Xaa8はI又はLであり、Xaa10はV、F又はAであり、Xaa11はM又はLであり、Xaa17はL又はIであり、
上記APC-結合ドメイン又は上記CD91受容体-結合ドメインは、上記タンパク質トランスダクションドメインが上記トランスロケーションペプチド(biii)である場合、シュードモナスエキソトキシンA(PE)結合ドメインIのアミノ酸配列を有さない、融合タンパク質。 - 前記APC-結合ドメイン又は前記CD91受容体-結合ドメインは、配列番号: 5、9、6、7及び8からなる群より選択される配列と少なくとも90%同一であるアミノ酸配列を含むポリペプチドである、請求項1に記載の融合タンパク質。
- 前記融合タンパク質のC末端に位置する小胞体リテンション配列を更に含む、請求項1に記載の融合タンパク質。
- 前記小胞体リテンション配列は、Lys-Asp-Glu-Leu(配列番号: 14)のアミノ酸配列を含む、請求項3に記載の融合タンパク質。
- 前記抗原が10個又は10個超のエピトープを含む場合、前記融合タンパク質は、そのC末端に前記小胞体リテンション配列を含まない、請求項1に記載の融合タンパク質。
- 前記タンパク質トランスダクションドメインは、前記融合ポリペプチド(bi)である、請求項1に記載の融合タンパク質。
- 前記タンパク質トランスダクションドメインは、前記T細胞-感作シグナル伝達ペプチド(bii)である、請求項1に記載の融合タンパク質。
- 前記タンパク質トランスダクションドメインと前記抗原との間に追加のリンカーを更に含み、前記追加のリンカーは、配列番号:15を含む、請求項7に記載の融合タンパク質。
- 前記タンパク質トランスダクションドメインは、前記トランスロケーションペプチド(biii)である、請求項1に記載の融合タンパク質。
- 前記APC-結合ドメイン又は前記CD91受容体-結合ドメインと前記トランスロケーションペプチドと間に追加のリンカーを更に含み、前記追加のリンカーは、配列番号:15を含む、請求項9に記載の融合タンパク質。
- 前記タンパク質トランスダクションドメインは、配列番号:30の配列を有する、請求項1に記載の融合タンパク質。
- (a) 請求項1に記載の治療的有効量の融合タンパク質と、
(b) アジュバントを含む、ワクチン組成物。 - 前記APC-結合ドメイン又は前記CD91受容体-結合ドメインは、配列番号: 5、9、6、7及び8からなる群より選択されるアミノ酸配列を含むポリペプチドである、請求項1に記載の融合タンパク質。
- 前記T細胞感作シグナル伝達ペプチドは、配列番号:1又は2と少なくとも90%同一であるアミノ酸配列を含む、請求項1に記載の融合タンパク質。
- 前記T細胞感作シグナル伝達ペプチドは、配列番号:1及び2からなる群より選択されるアミノ酸配列を含む、請求項14に記載の融合タンパク質。
- 前記トランスロケーションペプチドは、配列番号:3、20及び4からなる群より選択されるアミノ酸配列を含む、請求項1に記載の融合タンパク質。
- 病原体抗原特異的T細胞反応の向上を誘導するために使用する、請求項1から16のいずれかに記載の融合タンパク質又はワクチン組成物。
- 疾患細胞の細胞膜上のクラスI MHC分子を介して抗原を提示する疾患細胞を殺すために使用する、請求項1から17のいずれかに記載の融合タンパク質又はワクチン組成物。
- 前記疾患細胞は、がん細胞である、請求項18に記載の使用のための、融合タンパク質又はワクチン組成物。
- 病原体によって引き起こされる感染を予防する、治療する、及び/又は、感染によって引き起こされるを症状を最小限にするために使用する、請求項1から19のいずれかに記載の融合タンパク質又はワクチン組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261733879P | 2012-12-05 | 2012-12-05 | |
US61/733,879 | 2012-12-05 | ||
PCT/US2013/072753 WO2014089009A1 (en) | 2012-12-05 | 2013-12-03 | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017166010A Division JP6400810B2 (ja) | 2012-12-05 | 2017-08-30 | 抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016504308A true JP2016504308A (ja) | 2016-02-12 |
JP6279606B2 JP6279606B2 (ja) | 2018-02-14 |
Family
ID=50825669
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015546553A Expired - Fee Related JP6173479B2 (ja) | 2012-12-05 | 2013-12-03 | 抗原特異的t細胞反応を誘導するための免疫原エンハンサーとしての融合タンパク質 |
JP2015546546A Expired - Fee Related JP6279606B2 (ja) | 2012-12-05 | 2013-12-03 | 抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 |
JP2017130836A Expired - Fee Related JP6449384B2 (ja) | 2012-12-05 | 2017-07-04 | 抗原特異的t細胞反応を誘導するための免疫原エンハンサーとしての融合タンパク質 |
JP2017166010A Expired - Fee Related JP6400810B2 (ja) | 2012-12-05 | 2017-08-30 | 抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015546553A Expired - Fee Related JP6173479B2 (ja) | 2012-12-05 | 2013-12-03 | 抗原特異的t細胞反応を誘導するための免疫原エンハンサーとしての融合タンパク質 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017130836A Expired - Fee Related JP6449384B2 (ja) | 2012-12-05 | 2017-07-04 | 抗原特異的t細胞反応を誘導するための免疫原エンハンサーとしての融合タンパク質 |
JP2017166010A Expired - Fee Related JP6400810B2 (ja) | 2012-12-05 | 2017-08-30 | 抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 |
Country Status (12)
Country | Link |
---|---|
US (4) | US9481714B2 (ja) |
EP (2) | EP2928491B1 (ja) |
JP (4) | JP6173479B2 (ja) |
KR (3) | KR101746444B1 (ja) |
CN (7) | CN109553688A (ja) |
BR (2) | BR112015013135A2 (ja) |
DK (1) | DK2928491T3 (ja) |
ES (2) | ES2742739T3 (ja) |
IL (2) | IL239158A0 (ja) |
RU (2) | RU2619187C2 (ja) |
TW (2) | TWI490231B (ja) |
WO (2) | WO2014089036A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019531292A (ja) * | 2016-09-19 | 2019-10-31 | ザヴァックス ジェネティクス ワクチン カンパニー リミテッドThevax Genetics Vaccine Co., Ltd. | B型肝炎治療ワクチン |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
CN109553688A (zh) * | 2012-12-05 | 2019-04-02 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
CN107249629A (zh) * | 2015-02-26 | 2017-10-13 | 生控基因疫苗股份有限公司 | 包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物 |
WO2016196383A1 (en) * | 2015-06-01 | 2016-12-08 | Reber Genetics Co., Ltd. | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases |
JP2018521983A (ja) | 2015-07-16 | 2018-08-09 | バイオカイン セラピューティックス リミテッド | がんを治療するための組成物および方法 |
KR102153303B1 (ko) * | 2015-11-23 | 2020-09-09 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | Fmdv 및 e2 융합 단백질 및 이의 용도 |
US11186618B2 (en) * | 2016-09-21 | 2021-11-30 | The Research Foundation For Microbial Diseases Of Osaka University | Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide |
CN107991481A (zh) * | 2016-10-27 | 2018-05-04 | 武汉科前生物股份有限公司 | 一种检测猪伪狂犬病毒和口蹄疫病毒的二联阻断elisa抗体检测试剂盒及其应用 |
CN107937354A (zh) * | 2017-11-10 | 2018-04-20 | 南京天邦生物科技有限公司 | 2型猪圆环病毒及其应用 |
PL3762009T3 (pl) | 2018-03-08 | 2022-09-12 | Applied Molecular Transport Inc. | Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego |
CN109134667A (zh) * | 2018-09-19 | 2019-01-04 | 天康生物股份有限公司 | 融合蛋白及其制备方法、应用、表达系统和疫苗 |
JP2022512976A (ja) | 2018-11-07 | 2022-02-07 | アプライド モレキュラー トランスポート インコーポレイテッド | 異種ペイロードの経口送達のためのコリックス由来担体 |
CN109593136B (zh) * | 2018-12-26 | 2021-03-19 | 天康生物股份有限公司 | 禽副粘病毒融合蛋白及其制备方法、应用和用于鸽子的apmv疫苗 |
KR20220012256A (ko) * | 2019-05-24 | 2022-02-03 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
CN110051832B (zh) * | 2019-05-31 | 2020-11-10 | 四川农业大学 | 一种犬恶丝虫病疫苗 |
CN110452928A (zh) * | 2019-08-13 | 2019-11-15 | 成都天邦生物制品有限公司 | 一株pk-15稳定细胞株的构建及应用 |
AU2020329290A1 (en) * | 2019-08-13 | 2022-03-24 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta agonists |
CN110669142B (zh) * | 2019-09-30 | 2021-10-12 | 湖南农业大学 | 融合rgd的猪圆环病毒2型病毒样颗粒、突变型感染性克隆及其制备方法和应用 |
US20230173049A1 (en) * | 2019-12-31 | 2023-06-08 | The Johns Hopkins University | Fusion proteins and methods of use thereof |
CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
KR102507298B1 (ko) | 2020-12-21 | 2023-03-08 | 충남대학교산학협력단 | 면역증강을 위한 조성물 |
CN112812171B (zh) * | 2021-01-22 | 2022-04-08 | 浙江辉肽生命健康科技有限公司 | 具有氨基酸结构vvrkplnkegkkp的生物活性肽及其制备方法和应用 |
CN114539429B (zh) * | 2022-03-24 | 2022-07-29 | 上海普铭生物科技有限公司 | 融合蛋白组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069207A2 (en) * | 2003-02-04 | 2004-08-19 | University Of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
WO2004069206A2 (en) * | 2003-02-04 | 2004-08-19 | University Of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
US20120213811A1 (en) * | 2008-01-31 | 2012-08-23 | Healthbanks Usa Inc. | Chimeric hiv fusion proteins as vaccines |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US843505A (en) * | 1905-10-09 | 1907-02-05 | Alexandre Leonard Tombelaine | Safety closing device for miner's lamps. |
PT651805E (pt) * | 1992-07-17 | 2007-02-28 | Dana Farber Cancer Inst Inc | Método de ligação intracelular de moléculas-alvo |
US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
US7314632B1 (en) | 1997-07-11 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pseudomonas exotoxin A-like chimeric immunogens |
DK1000163T3 (da) * | 1997-07-11 | 2006-02-06 | Us Gov Health & Human Serv | Pseudomonas-exotoksin A-lignende kimære immunogener |
ATE359084T1 (de) * | 1998-02-20 | 2007-05-15 | Univ Miami | Modifizierter hitzeschockprotein/peptidantigen komplex |
WO1999045127A2 (en) * | 1998-03-06 | 1999-09-10 | Oxford Biomedica (Uk) Limited | Enhanced prodrug activation |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
WO2000049041A1 (fr) * | 1999-02-19 | 2000-08-24 | Sumitomo Electric Industries, Ltd. | Preparations proteiques |
JP4637368B2 (ja) * | 1999-04-14 | 2011-02-23 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法 |
EP1222289B1 (en) * | 1999-10-20 | 2008-04-16 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
US8128922B2 (en) * | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
CA2453528C (en) * | 2001-08-01 | 2011-07-26 | Cellomics, Inc. | Novel fusion proteins and assays for molecular binding |
US7235631B2 (en) * | 2002-02-07 | 2007-06-26 | Mayo Foundation For Medical Education And Research | ICOS mutants |
WO2004087754A1 (en) * | 2003-04-03 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
IL164799A0 (en) * | 2002-04-25 | 2005-12-18 | Univ Connecticut | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
US7595054B2 (en) * | 2003-06-09 | 2009-09-29 | Healthbanks Biotech Co., Ltd. | Fusion antigen used as vaccine |
US7335361B2 (en) | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
EP1756147A2 (en) * | 2004-06-01 | 2007-02-28 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
JP4474264B2 (ja) * | 2004-08-20 | 2010-06-02 | 生寶生物科技股▲ふん▼有限公司 | 子宮頸癌抑制の融合蛋白 |
WO2006135428A2 (en) * | 2004-10-04 | 2006-12-21 | Trinity Biosystems, Inc. | Methods and compositions for inducing an immune response against multiple antigens |
US7964200B2 (en) * | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
US7465455B2 (en) | 2006-07-05 | 2008-12-16 | Healthbanks Biotech Co., Ltd. | Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine |
WO2008047243A2 (en) * | 2006-08-29 | 2008-04-24 | Forhumantech. Co., Ltd. | Pharmaceutical composition for suppression of apoptosis and method for delivering the same |
MX2009002893A (es) * | 2006-09-18 | 2009-07-10 | Raptor Pharmaceutical Inc | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). |
US7887801B2 (en) * | 2007-07-13 | 2011-02-15 | Topotarget Germany Ag | Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
WO2009036349A1 (en) * | 2007-09-12 | 2009-03-19 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
EP2078726A1 (en) * | 2008-01-09 | 2009-07-15 | Vision 7 GmbH | Secretable HIV entry inhibitory peptides for therapy of HIV infection |
WO2010040023A2 (en) * | 2008-10-03 | 2010-04-08 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for protein delivery |
PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
CN109553688A (zh) * | 2012-12-05 | 2019-04-02 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
-
2013
- 2013-12-03 CN CN201811287071.9A patent/CN109553688A/zh active Pending
- 2013-12-03 CN CN201380063896.1A patent/CN104918637B/zh not_active Expired - Fee Related
- 2013-12-03 ES ES13860021T patent/ES2742739T3/es active Active
- 2013-12-03 KR KR1020167029734A patent/KR101746444B1/ko active IP Right Grant
- 2013-12-03 CN CN201710718246.6A patent/CN107434827B/zh not_active Expired - Fee Related
- 2013-12-03 WO PCT/US2013/072804 patent/WO2014089036A1/en active Application Filing
- 2013-12-03 BR BR112015013135A patent/BR112015013135A2/pt not_active Application Discontinuation
- 2013-12-03 US US14/095,760 patent/US9481714B2/en active Active
- 2013-12-03 US US14/095,947 patent/US9339536B2/en active Active
- 2013-12-03 JP JP2015546553A patent/JP6173479B2/ja not_active Expired - Fee Related
- 2013-12-03 EP EP13860917.7A patent/EP2928491B1/en not_active Not-in-force
- 2013-12-03 ES ES13860917T patent/ES2701448T3/es active Active
- 2013-12-03 CN CN201811287073.8A patent/CN109608550B/zh not_active Expired - Fee Related
- 2013-12-03 WO PCT/US2013/072753 patent/WO2014089009A1/en active Application Filing
- 2013-12-03 RU RU2015122368A patent/RU2619187C2/ru not_active IP Right Cessation
- 2013-12-03 CN CN201811287074.2A patent/CN109535259A/zh active Pending
- 2013-12-03 BR BR112015013183A patent/BR112015013183A2/pt not_active Application Discontinuation
- 2013-12-03 CN CN201811288421.3A patent/CN109535228B/zh not_active Expired - Fee Related
- 2013-12-03 DK DK13860917.7T patent/DK2928491T3/en active
- 2013-12-03 JP JP2015546546A patent/JP6279606B2/ja not_active Expired - Fee Related
- 2013-12-03 KR KR1020157014330A patent/KR101650364B1/ko active IP Right Grant
- 2013-12-03 CN CN201380063867.5A patent/CN104884082B/zh not_active Expired - Fee Related
- 2013-12-03 RU RU2015122371A patent/RU2631002C2/ru not_active IP Right Cessation
- 2013-12-03 KR KR1020157014327A patent/KR101671291B1/ko active IP Right Grant
- 2013-12-03 EP EP13860021.8A patent/EP2928493B1/en not_active Not-in-force
- 2013-12-05 TW TW102144581A patent/TWI490231B/zh active
- 2013-12-05 TW TW102144580A patent/TWI486359B/zh active
-
2015
- 2015-06-03 IL IL239158A patent/IL239158A0/en unknown
- 2015-06-03 IL IL239157A patent/IL239157A0/en unknown
-
2016
- 2016-04-13 US US15/098,210 patent/US9676826B2/en not_active Expired - Fee Related
- 2016-09-22 US US15/273,588 patent/US9676827B2/en active Active
-
2017
- 2017-07-04 JP JP2017130836A patent/JP6449384B2/ja not_active Expired - Fee Related
- 2017-08-30 JP JP2017166010A patent/JP6400810B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069207A2 (en) * | 2003-02-04 | 2004-08-19 | University Of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
WO2004069206A2 (en) * | 2003-02-04 | 2004-08-19 | University Of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
US20120213811A1 (en) * | 2008-01-31 | 2012-08-23 | Healthbanks Usa Inc. | Chimeric hiv fusion proteins as vaccines |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019531292A (ja) * | 2016-09-19 | 2019-10-31 | ザヴァックス ジェネティクス ワクチン カンパニー リミテッドThevax Genetics Vaccine Co., Ltd. | B型肝炎治療ワクチン |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6400810B2 (ja) | 抗原特異的t細胞反応を誘導する免疫原エンハンサーとして使用する融合タンパク質 | |
AU2016271144B2 (en) | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases | |
JP2018507860A (ja) | 抗原特異的t細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物 | |
de Jesús Jiménez-Chávez et al. | B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer | |
Cazorla et al. | Redirection of the immune response to the functional catalytic domain of cruzipain improves protective immunity against Trypanosoma cruzi infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170830 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6279606 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |